Skip to content. | Skip to navigation

Personal tools
Log in
Sections
You are here: Home › Faculty › Dr. Aly Karsan › Publications-Complete › Publications-Aly Karsan

Publications-Aly Karsan

by Mhairi Sigrist — last modified Jan 12, 2012 12:44 PM
Updated Jan 2011
  1. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012 Jan;226(1):7-16
  2. Dauphinee SM, Voelcker V, Tebaykina Z, Wong F, Karsan A. Heterotrimeric Gi/Go proteins modulate endothelial TLR signaling independent of the MyD88-dependent pathway. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2246-53
  3. Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest. 2011 Oct 3;121(10):4095-105
  4. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Rüschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 2011 Sep 22;118(12):3350-8
  5. Chang AC, Fu Y, Garside VC, Niessen K, Chang L, Fuller M, Setiadi A, Smrz J, Kyle A, Minchinton A, Marra M, Hoodless PA, Karsan A. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. Dev Cell. 2011 Aug 16;21(2):288-300
  6. Wegrzyn J, Lam JC, Karsan A. Mouse models of myelodysplastic syndromes. Leuk Res. 2011 Jul;35(7):853-62. Epub 2011 Apr 3. Review
  7. Fu Y, Chang AC, Fournier M, Chang L, Niessen K, Karsan A. RUNX3 maintains the mesenchymal phenotype after termination of the Notch signal. J Biol Chem. 2011 Apr 1;286(13):11803-13
  8. Starczynowski DT, Vercauteren S, Sung S, Brooks-Wilson A, Lam WL, Karsan A.Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res. 2011 Apr;35(4):444-7.Authors Proof
  9. Jädersten M, Karsan A. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica. 2011 Feb;96(2):177-80.
  10. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival.Exp Hematol. 2011 Feb;39(2):167-178.e4.Authors Proof
  11. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan A. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2011 Jan 13;117(2):595-607.Authors proof
  12. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica. 2010 Dec;95(12):2157-60. Epub 2010 Aug 16.
  13. Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, Tsang P, Leitch H, Karsan A. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. Am J Clin Pathol. 2010 Jul;134(1):119-26. Authors Proof
  14. Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr;24(2):343-59.Authors Proof
  15. Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010 Mar 1;9(5):855-6. Epub 2010 Mar 11. Authors proof
  16. Murphy D, Parker J, Zhou M, Fadlelmola FM, Steidl C, Karsan A, Gascoyne RD, Chen H, Banerjee D. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer. 2010 Jan 26;9:14.
  17. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 2010 May;79(3):217-23. Epub 2010 Jan 18.
  18. Vrljicak P, Chang AC, Morozova O, Wederell ED, Niessen K, Marra MA, Karsan A, Hoodless PA. Genomic analysis distinguishes phases of early development of the mouse atrio-ventricular canal. Physiol Genomics. 2010 Feb 4;40(3):150-7. Epub 2009 Dec 1.
  19. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010 Jan;16(1):49-58. Epub 2009 Nov 8.Authors Proof
  20. Fu Y, Chang A, Chang L, Niessen K, Eapen S, Setiadi A, Karsan A. Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells. J Biol Chem. 2009 Jul 17;284(29):19452-62. Epub 2009 May 27.
  21. Vercauteren SM, Bashashati A, Wu D, Brinkman RR, Eaves C, Eaves A, Karsan A. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias. Leuk Res. 2009 Dec;33(12):1636-42. Epub 2009 May 2.
  22. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008 Oct 15;112(8):3412-24. Epub 2008 Jul 28.
  23. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol. 2008 Jul 28;182(2):315-25.
  24. Niessen K, Karsan A. Notch signaling in cardiac development. Circ Res. 2008 May 23;102(10):1169-81. Review.
  25. Karsan A. Notch and integrin affinity: a sticky situation. Sci Signal. 2008 Jan 15;1(2):pe2.
  26. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007 Nov 26;204(12):2935-48. Epub 2007 Nov 5.
  27. Zhande R, Dauphinee SM, Thomas JA, Yamamoto M, Akira S, Karsan A. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1 receptor-associated kinase 1-MyD88 interaction. Mol Cell Biol. 2007 Nov;27(21):7394-404. Epub 2007 Sep 4.
  28. Wu C, Cipollone J, Maines-Bandiera S, Tan C, Karsan A, Auersperg N, Roskelley CD. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation. 2008 Feb;76(2):193-205. Epub 2007 Jul 2.
  29. Larrivée B, Karsan A. Involvement of marrow-derived endothelial cells in vascularization. Handb Exp Pharmacol. 2007;(180):89-114. Review.
  30. Niessen K, Karsan A. Notch signaling in the developing cardiovascular system. Am J Physiol Cell Physiol. 2007 Jul;293(1):C1-11. Epub 2007 Mar 21. Review.
  31. Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2467-74. Epub 2007 Jan 19.
  32. Noseda M, Karsan A. Notch and minichromosome maintenance (MCM) proteins: integration of two ancestral pathways in cell cycle control. Cell Cycle. 2006 Dec;5(23):2704-9. Epub 2006 Dec 1. Review.
  33. Larrivée B, Olive PL, Karsan A. Tissue distribution of endothelial cells in vivo following intravenous injection. Exp Hematol. 2006 Dec;34(12):1741-5.
  34. Noseda M, Fu Y, Niessen K, Wong F, Chang L, McLean G, Karsan A. Smooth Muscle alpha-actin is a direct target of Notch/CSL. Circ Res. 2006 Jun 23;98(12):1468-70. Epub 2006 Jun 1.
  35. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest. 2006 Jan;86(1):9-22. Review.
  36. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006 Mar 15;107(6):2223-33. Epub 2005 Nov 15. Review.
  37. Murphy S, Larrivée B, Pollet I, Craig KS, Williams DE, Huang XH, Abbott M, Wong F, Curtis C, Conrads TP, Veenstra T, Puri M, Hsiang Y, Roberge M, Andersen RJ, Karsan A. Identification of sokotrasterol sulfate as a novel proangiogenic steroid. Circ Res. 2006 Aug 4;99(3):257-65. Epub 2006 Jun 22.
  38. Larrivée B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol. 2005 Sep 1;175(5):3015-24.
  39. Larrivée B, Niessen K, Pollet I, Corbel SY, Long M, Rossi FM, Olive PL, Karsan A. Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J Immunol. 2005 Sep 1;175(5):2890-9.
  40. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J. 2005 Oct;19(12):1728-30. Epub 2005 Jul 27.
  41. Hood BL, Lucas DA, Kim G, Chan KC, Blonder J, Issaq HJ, Veenstra TD, Conrads TP, Pollet I, Karsan A. Quantitative analysis of the low molecular weight serum proteome using 18O stable isotope labeling in a lung tumor xenograft mouse model. J Am Soc Mass Spectrom. 2005 Aug;16(8):1221-30.
  42. Noseda M, Niessen K, McLean G, Chang L, Karsan A. Notch-dependent cell cycle arrest is associated with downregulation of minichromosome maintenance proteins. Circ Res. 2005 Jul 22;97(2):102-4. Epub 2005 Jun 23.
  43. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, Harrison D, Law J, Hayes M, Stillwell M, Xiao Z, Conrads TP, Veenstra T. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005 Aug;51(8):1525-8. Epub 2005 Jun 10.
  44. Karsan A, Blonder J, Law J, Yaquian E, Lucas DA, Conrads TP, Veenstra T. Proteomic analysis of lipid microdomains from lipopolysaccharide-activated human endothelial cells. J Proteome Res. 2005 Mar-Apr;4(2):349-57.
  45. Karsan A. The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol. 2005 Jan;83(1):14-23. Review.
  46. Karsan A, Pollet I, Yu LR, Chan KC, Conrads TP, Lucas DA, Andersen R, Veenstra T. Quantitative proteomic analysis of sokotrasterol sulfate-stimulated primary human endothelial cells. Mol Cell Proteomics. 2005 Feb;4(2):191-204. Epub 2004 Dec 20.
  47. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol. 2004 Oct;24(20):8813-22.
  48. Larrivée B, Karsan A. Isolation and culture of primary endothelial cells. Methods Mol Biol. 2005;290:315-29.
  49. MacKenzie F, Duriez P, Larrivée B, Chang L, Pollet I, Wong F, Yip C, Karsan A. Notch4-induced inhibition of endothelial sprouting requires the ankyrin repeats and involves signaling through RBP-Jkappa. Blood. 2004 Sep 15;104(6):1760-8. Epub 2004 Jun 8.
  50. Wong F, Hull C, Zhande R, Law J, Karsan A. Lipopolysaccharide initiates a TRAF6-mediated endothelial survival signal. Blood. 2004 Jun 15;103(12):4520-6. Epub 2004 Mar 2.
  51. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, Shahidi R, Dorovini-Zis K, Li L, Beckstead B, Durand RE, Hoodless PA, Karsan A. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res. 2004 Apr 16;94(7):910-7. Epub 2004 Feb 26.
  52. MacKenzie F, Duriez P, Wong F, Noseda M, Karsan A. Notch4 inhibits endothelial apoptosis via RBP-Jkappa-dependent and -independent pathways. J Biol Chem. 2004 Mar 19;279(12):11657-63. Epub 2003 Dec 29.
  53. Harfouche R, Gratton JP, Yancopoulos GD, Noseda M, Karsan A, Hussain SN. Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases. FASEB J. 2003 Aug;17(11):1523-5. Epub 2003 Jun 17.
  54. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood. 2003 Sep 1;102(5):1740-2. Epub 2003 Apr 24.
  55. Larrivée B, Lane DR, Pollet I, Olive PL, Humphries RK, Karsan A. Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells. J Biol Chem. 2003 Jun 13;278(24):22006-13. Epub 2003 Mar 30.
  56. Levkau B, Kenagy RD, Karsan A, Weitkamp B, Clowes AW, Ross R, Raines EW. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ. 2002 Dec;9(12):1360-7.
  57. Zheng X, Karsan A, Duronio V, Chu F, Walker DC, Bai TR, Schellenberg RR. Interleukin-3, but not granulocyte-macrophage colony-stimulating factor and interleukin-5, inhibits apoptosis of human basophils through phosphatidylinositol 3-kinase: requirement of NF-kappaB-dependent and -independent pathways. Immunology. 2002 Nov;107(3):306-15.
  58. Hull C, McLean G, Wong F, Duriez PJ, Karsan A. Lipopolysaccharide signals an endothelial apoptosis pathway through TNF receptor-associated factor 6-mediated activation of c-Jun NH2-terminal kinase. J Immunol. 2002 Sep 1;169(5):2611-8.
  59. Litwin C, Leong KG, Zapf R, Sutherland H, Naiman SC, Karsan A. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol. 2002 May;70(1):22-30.
  60. Leong KG, Hu X, Li L, Noseda M, Larrivée B, Hull C, Hood L, Wong F, Karsan A. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol. 2002 Apr;22(8):2830-41.
  61. Roskelley CD, Williams DE, McHardy LM, Leong KG, Troussard A, Karsan A, Andersen RJ, Dedhar S, Roberge M. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res. 2001 Sep 15;61(18):6788-94.
  62. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, Shapiro S, Wright JL. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001 Aug;81(8):1119-31.
  63. Imanishi T, Hano T, Nishio I, Han DK, Schwartz SM, Karsan A. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from endothelial cells. Jpn Circ J. 2001 Jun;65(6):556-60. Erratum in: Jpn Circ J 2002 Dec;66(12):1185.
  64. Leong KG, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol. 2000 Oct;15(4):1303-25. Review.
  65. Duriez PJ, Wong F, Dorovini-Zis K, Shahidi R, Karsan A. A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem. 2000 Jun 16;275(24):18099-107.
  66. Larrivée B, Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000 May;5(5):447-56. Review.
  67. Zen K, Karsan A, Stempien-Otero A, Yee E, Tupper J, Li X, Eunson T, Kay MA, Wilson CB, Winn RK, Harlan JM. NF-kappaB activation is required for human endothelial survival during exposure to tumor necrosis factor-alpha but not to interleukin-1beta or lipopolysaccharide. J Biol Chem. 1999 Oct 1;274(40):28808-15.
  68. Schwartz BR, Karsan A, Bombeli T, Harlan JM. A novel beta 1 integrin-dependent mechanism of leukocyte adherence to apoptotic cells. J Immunol. 1999 Apr 15;162(8):4842-8.
  69. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem. 1999 Mar 19;274(12):8039-45.
  70. Mitra D, Kim J, MacLow C, Karsan A, Laurence J. Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Am J Hematol. 1998 Dec;59(4):279-87.
  71. Hu X, Yee E, Harlan JM, Wong F, Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood. 1998 Oct 15;92(8):2759-65.
  72. Zen K, Karsan A, Eunson T, Yee E, Harlan JM. Lipopolysaccharide-induced NF-kappaB activation in human endothelial cells involves degradation of IkappaBalpha but not IkappaBbeta. Exp Cell Res. 1998 Sep 15;243(2):425-33.
  73. Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM. A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun. 1998 Aug 19;249(2):361-5.
  74. Choi KB, Wong F, Harlan JM, Chaudhary PM, Hood L, Karsan A. Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway. J Biol Chem. 1998 Aug 7;273(32):20185-8.
  75. Karsan A, Cornejo CJ, Winn RK, Schwartz BR, Way W, Lannir N, Gershoni-Baruch R, Etzioni A, Ochs HD, Harlan JM. Leukocyte Adhesion Deficiency Type II is a generalized defect of de novo GDP-fucose biosynthesis. Endothelial cell fucosylation is not required for neutrophil rolling on human nonlymphoid endothelium. J Clin Invest. 1998 Jun 1;101(11):2438-45.
  76. Karsan A, Yee E, Poirier GG, Zhou P, Craig R, Harlan JM. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol. 1997 Dec;151(6):1775-84.
  77. Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest. 1997 Sep;77(3):257-67.
  78. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997 Apr 1;89(7):2429-42.
  79. Pang XP, Hershman JM, Karsan A. TNF-alpha induction of A1 expression in human cancer cells. Oncol Res. 1997;9(11-12):623-7.
  80. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem. 1996 Nov 1;271(44):27201-4.
  81. Karsan A, Yee E, Kaushansky K, Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood. 1996 Apr 15;87(8):3089-96.
  82. Karsan A, Harlan JM. Modulation of endothelial cell apoptosis: mechanisms and pathophysiological roles. J Atheroscler Thromb. 1996;3(2):75-80. Review.
  83. Karsan A, Gascoyne RD, Coupland RW, Shepherd JD, Phillips GL, Horsman DE. Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma. 1993 Aug;10(6):433-41.
  84. Karsan A, Maclaren I, Conn D, Wadsworth L. An evaluation of hemoglobin determination using sodium lauryl sulfate. Am J Clin Pathol. 1993 Aug;100(2):123-6.
  85. Karsan A, MacLaren I, Pi D, Wadsworth L. Clinically significant heparin carryover on the ACL 300R. Am J Clin Pathol. 1992 Aug;98(2):240-2.

There are currently no criteria on which to search. Please add them using the 'criteria' tab.

Document Actions
Page last modified Jan 12, 2012